clinical trial · NCT05523895
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Irritability Associated With Autism Spectrum DisorderPimavanserinPlacebo
brief summary
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
started
Aug 9, 2022
primary completion
Sep 27, 2024
completion
Sep 27, 2024
last updated
Aug 24, 2025
detailed description
This study will be conducted as a 6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (5 through 17 years of age) with ASD with irritability, agitation, or self-injurious behaviors.
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol